Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1143-1148

  Wang, Wei ^a   Sun, Yueping ^b   Li, Xinxing ^a   Li, Hui ^b   Chen, Yuying ^b   Tian, Ye ^b   Yi, Jing ^b   Wang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Cisplatin; Drug resistance; Emodin; Gallbladder cancer; Reactive oxygen species; Survivin

Indexed keywords

CISPLATIN; EMODIN; REACTIVE OXYGEN METABOLITE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GALLBLADDER CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; EMODIN; GALLBLADDER NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053161001     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1390     Document Type: Article

References (45)

1. Grobmyer SR, Lieberman MD and Daly JM: Gallbladder cancer in the twentieth century: single institution's experience. World J Surg 28: 47-49, 2004. (Pubitemid 38095792)
2. Qayyum A and Mujtaba I: Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder. J Pak Med Assoc 57: 71-74, 2007. (Pubitemid 350188257)
3. Huang XZ, Wang J, Huang C, et al: Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7: 468-475, 2008. (Pubitemid 351847069)
4. Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7: 542-547, 2001.
5. Thomas S and Shah G: Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther 4: 1226-1233, 2005.
6. Yang J, Li H, Chen YY, et al: Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med 37: 2027-2041, 2004. (Pubitemid 39491322)
7. Jing Y, Yang J, Wang Y, et al: Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic Biol Med 40: 2183-2197, 2006. (Pubitemid 43903104)
8. Wang HH and Chung JG: Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol 35: 262-266, 1997.
9. Chang CH, Lin CC, Yang JJ, Namba T and Hattori M: Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med 24: 139-142, 1996. (Pubitemid 126765683)
10. Yim H, Lee YH, Lee CH and Lee SK: Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med 65: 9-13, 1999. (Pubitemid 29077420)
11. Cai J, Razzak A, Hering J, et al: Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. JPEN J Parenter Enteral Nutr 32: 190-196, 2008. (Pubitemid 351464893)
12. Chang CJ, Ashendel CL, Geahlen RL, McLaughlin JL and Waters DJ: Oncogene signal transduction inhibitors from medicinal plants. In Vivo 10: 185-190, 1996. (Pubitemid 26001182)
13. Chen YC, Shen SC, Lee WR, et al: Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64: 1713-1724, 2002.
14. Jing X, Ueki N, Cheng J, Imanishi H and Hada T: Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Jpn J Cancer Res 93: 874-882, 2002. (Pubitemid 35012248)
15. Srinivas G, Anto RJ, Srinivas P, Vidhyalakshmi S, Senan VP and Karunagaran D: Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol 473: 117-125, 2003. (Pubitemid 36929875)
16. Zhang L, Lau YK, Xi L, et al: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16: 2855-2863, 1998. (Pubitemid 28383270)
17. Cha TL, Qiu L, Chen CT, Wen Y and Hung MC: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65: 2287-2295, 2005. (Pubitemid 40490138)
18. Huang Q, Shen HM, Shui G, Wenk MR and Ong CN: Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res 66: 5807-5815, 2006. (Pubitemid 43927135)
19. Kim MS, Park MJ, Kim SJ, et al: Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int J Oncol 27: 839-846, 2005.
20. Kwak HJ, Park MJ, Park CM, et al: Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118: 2711-2720, 2006.
21. Muto A, Hori M, Sasaki Y, et al: Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6: 987-994, 2007. (Pubitemid 46554568)
22. Shieh DE, Chen YY, Yen MH, Chiang LC and Lin CC: Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci 74: 2279-2290, 2004.
23. Srinivas G, Babykutty S, Sathiadevan PP and Srinivas P: Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 27: 591-608, 2007. (Pubitemid 47282445)
24. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
25. Pervaiz S and Clement MV: Tumor intracellular redox status and drug resistance - serendipity or a causal relationship? Curr Pharm Des 10: 1969-1977, 2004. (Pubitemid 38647581)
26. Singh N, Azmi S, Sheriff A, Dhawan D and Khanna N: Differential sensitivity of murine myeloid FDC-P1 cells and apoptosis resistant mutant(s) to anticancer drugs. Mutat Res 474: 105-112, 2001. (Pubitemid 32184759)
27. Furusawa S, Kimura E, Kisara S, et al: Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull 24: 474-479, 2001. (Pubitemid 32499469)
28. Renschler MF: The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 40: 1934-1940, 2004.
29. Bailey HH: L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111-112: 239-254, 1998.
30. Maeda H, Hori S, Ohizumi H, et al: Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 11: 737-746, 2004. (Pubitemid 39023120)
31. Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C and Simon DI: Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol 21: 759-764, 2001. (Pubitemid 32448765)
32. Husbeck B, Peehl DM and Knox SJ: Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38: 50-57, 2005. (Pubitemid 39626908)
33. Kitamura K, Minami Y, Yamamoto K, et al: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14: 1743-1750, 2000.
34. Cai J, Niu X, Chen Y, et al: Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 10: 41-51, 2008. (Pubitemid 351170711)
35. Yi J, Yang J, He R, et al: Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64: 108-116, 2004. (Pubitemid 38114088)
36. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
37. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
38. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216, 2005.
39. Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372, 2005.
40. Mitsiades CS, Mitsiades N, Poulaki V, et al: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673-5683, 2002. (Pubitemid 35333000)
41. Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142, 2001. (Pubitemid 32096826)
42. Zhu L, Fukuda S, Cordis G, Das DK and Maulik N: Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 508: 369-374, 2001. (Pubitemid 33135473)
43. Qi H and Ohh M: The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res 63: 7076-7080, 2003. (Pubitemid 37413442)
44. Reed JC: The Survivin saga goes in vivo. J Clin Invest 108: 965-969, 2001.
45. Wang J and Yi J: Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 7: 1875-1884, 2008.